<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F113D73A-143F-41B6-9680-98AF837D51DF"><gtr:id>F113D73A-143F-41B6-9680-98AF837D51DF</gtr:id><gtr:name>University of Antwerp</gtr:name><gtr:address><gtr:line1>Universiteitsplein 1</gtr:line1><gtr:line4>Antwerp</gtr:line4><gtr:line5>B-2610</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1E0E310-885F-4DC7-B908-31AACD12FAFA"><gtr:id>C1E0E310-885F-4DC7-B908-31AACD12FAFA</gtr:id><gtr:name>Boehringer Ingelheim</gtr:name><gtr:address><gtr:line1>Corporate Division Communications</gtr:line1><gtr:line2>Binger Strasse 173</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F113D73A-143F-41B6-9680-98AF837D51DF"><gtr:id>F113D73A-143F-41B6-9680-98AF837D51DF</gtr:id><gtr:name>University of Antwerp</gtr:name><gtr:address><gtr:line1>Universiteitsplein 1</gtr:line1><gtr:line4>Antwerp</gtr:line4><gtr:line5>B-2610</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1E0E310-885F-4DC7-B908-31AACD12FAFA"><gtr:id>C1E0E310-885F-4DC7-B908-31AACD12FAFA</gtr:id><gtr:name>Boehringer Ingelheim</gtr:name><gtr:address><gtr:line1>Corporate Division Communications</gtr:line1><gtr:line2>Binger Strasse 173</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0D8E8879-0792-49DD-9598-3984A6BEA513"><gtr:id>0D8E8879-0792-49DD-9598-3984A6BEA513</gtr:id><gtr:firstName>Alessio</gtr:firstName><gtr:surname>Ciulli</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FG023123%2F2"><gtr:id>0E81F16A-93CA-4CE4-9ED6-1FB701974D46</gtr:id><gtr:title>DISSECTING AND EXPLOITING MOLECULAR RECOGNITION AT PROTEIN-PROTEIN INTERFACES</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>BB/G023123/2</gtr:grantReference><gtr:abstractText>Proteins regulate many of the processes that are crucial for the activity of a living cell. In order to successfully carry out their biological function, proteins often interact in complex with other proteins. The principal subject of the proposed research concerns the development of new approaches to advance our understanding of protein-protein interactions and of how we could disrupt these interactions using the binding of a small molecule. In this project, I focus on studying the binding of small molecules to protein interfaces. I pose the following questions: what features of protein interfaces determine binding and activity (or lack thereof) of a small molecule? Can we modify protein interfaces so that a small molecule can 'stick' to the surface better and better? What can we learn from these new interfaces? How can we use such information to discover new compounds that could function in the cell by binding tightly to these sites? To interrogate protein interfaces, I will first use protein engineering, a technique to generate mutations on a protein by changing amino acids, the building blocks of proteins, from one type to another. I will make mutations in a defined manner, by replacing large amino acids at the protein interface with smaller and smaller ones, hence creating larger and larger cavities. The location and strength of small molecules bound to these engineered pockets will be determined. This will provide useful information to find other protein interfaces that may be functional in living organisms, and that may have the potential to be disrupted using small molecules. Secondly, I will exploit this knowledge further to facilitate identification of small molecules that function by disrupting a protein interface. I will develop new methods to detect small molecules that bind together to adjacent sites of the interface. For this purpose, I will use nuclear magnetic resonance (NMR) spectroscopy, a technique that allows monitoring the hydrogen atoms of small molecules and that can report if these are bound to a protein close to one another. I will also make crystals of the protein in which the interface is accessible to small molecules, and let these molecules react together as they are bound close to each other at the protein surface. Since the structure of a small molecule bound to the protein can be determined directly by shooting X-ray radiations at the protein crystal, a technique called X-ray crystallography, this is a rapid way of identifying any compound that has successfully assembled at the protein interface. The research is important and exciting for the following reasons: 1. Protein interfaces tend to be relatively flat and featureless, as they were not 'evolved' by nature to bind small molecules. The modulation of protein-protein interactions using small molecules is therefore a challenging task, and is at the forefront of molecular recognition. 2. A new scientific horizon is to advance our understanding of biological systems by disrupting pathways and networks in a selective fashion inside the cell. As protein-protein interactions occur widely within the cell, their modulation using small molecules offers an opportunity to interrogate and discover new biology. 3. The disruption of protein-protein complexes offers a novel and general mechanism to develop new medicines. In conclusion, this research has the potential to significantly impact on the way new biology and new drugs will be discovered in the future, with wider benefits to society and exciting opportunities in the fight against disease.</gtr:abstractText><gtr:technicalSummary>The overall objective of this fellowship application is to advance our fundamental understanding of molecular recognition at protein interfaces by small organic compounds. The project will employ a unique combination of molecular biology and biophysical studies of protein-ligand interactions to dissect the nature of non-covalent interactions at protein interfaces, and to exploit such knowledge with the goal of aiding small molecule design. I will study the interaction of small peptides and fragment-like compounds (MW &amp;lt; 300 Da) to the tumour suppressor Von Hippel-Lindau (pVHL), a protein which is part of a complex responsible for the degradation of the Hypoxia-Inducible Factor (HIF-1) inside the cell. I will use protein engineering to make larger and larger cavities at the pVHL:HIF-1 interface with the aim to bind small molecule with increasingly higher affinities. I will study the fundamental changes to the recognition of the small molecules in terms of structure (using X-ray crystallography) and thermodynamics (using low c value isothermal titration calorimetry). This information will provide a platform for future studies in the following two directions: 1) to find structurally similar protein interfaces that may be druggable, using computational tools and structural databases; 2) to facilitate discovery of novel small molecules that bind with high affinity and specificity to a protein interface, using intermolecular Nuclear Overhauser Effect to identify fragments binding at adjacent sites by NMR spectroscopy, and Dynamic Combinatorial X-ray Crystallography to assemble fragments together in the presence of a protein crystal, with the aim of selecting the highest affinity compound. Together these studies will provide significant new insights into the principles that govern the modulation of protein-protein interactions using small molecules, and new tools for studying systems of biological importance and therapeutic potential.</gtr:technicalSummary><gtr:fund><gtr:end>2015-07-07</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2013-04-08</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>307126</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>the video is being used to support the dissemination of the Dundee-Messina project funded by the MIUR programme Messaggeri della Conoscenza</gtr:description><gtr:id>7A7DA9C6-C773-4327-B8D0-F05F54EDA542</gtr:id><gtr:impact>impact not yet realised - video just published online</gtr:impact><gtr:outcomeId>5464d49c7154c1.91505523</gtr:outcomeId><gtr:title>Video of the Dundee-Messina project - Ciulli Lab</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:url>https://www.youtube.com/watch?v=JFF7QN22yEI</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Antwerp</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Ion mobility mass spectrometry to interrogate the structure and assembly of multisubunit protein complexes</gtr:description><gtr:id>9539B143-42CE-42BE-BDFF-9587136E97BF</gtr:id><gtr:impact>Bulatov, E., Martin, E.M., Chatterjee, S., Knebel, A., Shimamura, S., Konijnenberg, A., Johnson, C., Zinn, N., Grandi, P., Sobott, F., Ciulli, A.* Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2):ElonginBC:Cullin5:RING-box protein 2 (Rbx2). J. Biol. Chem. 2015, 290(7), 4178-4198.</gtr:impact><gtr:outcomeId>56d95f234ed807.97143030-1</gtr:outcomeId><gtr:partnerContribution>They performed native nanoelectrospray ionization mass spectrometry and traveling wave ion mobility MS experiments on our samples and analyzed data.</gtr:partnerContribution><gtr:piContribution>We expressed and purified component subunits of the SOCS2-CRL E3 ligases assembled into specific complexes and provided the samples to the collaborator (Prof. Frank Sobott research team)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>BioNMR collaborative project BIO-NMR-00169 entitled: Targeting and characterising multi-protein complexes in Fragment-based drug discovery. Small molecules binding to VHL E3 Ubiquitin Ligase and protein binding partners studied by NMR spectroscopy.</gtr:description><gtr:id>E30FD447-D9A3-4D10-9422-281BADC03C52</gtr:id><gtr:impact>multi-disciplinary collaboration, involving NMR spectroscopy, biophysics, protein purification and characterization and drug discovery.

Dias, D.M., Ciulli, A.* NMR approaches in structure-based lead discovery: Recent developments and new frontiers for targeting multi-protein complexes. Prog Biophys Mol Biol, 2014, 116(2-3), 101-112</gtr:impact><gtr:outcomeId>5464d104304829.30408051-1</gtr:outcomeId><gtr:partnerContribution>provide access to NMR instrumentation and facilities and provided intellectual input</gtr:partnerContribution><gtr:piContribution>purified protein samples for NMR spectroscopic studies and provided intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boehringer Ingelheim</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>PROTAC collaboration with Boehringer Ingelheim</gtr:description><gtr:id>C4049293-449B-4777-89D8-ABF12BF26F38</gtr:id><gtr:impact>confidential</gtr:impact><gtr:outcomeId>58cab244edcf51.92234293-1</gtr:outcomeId><gtr:partnerContribution>drug discovery research</gtr:partnerContribution><gtr:piContribution>drug discovery research</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>BioNMR collaborative project 261863 proposal no. BIO-NMR-00211 entitled: Structural modelling and dynamics of the Bromodomain Adjacent to Zinc finger domain containing protein 2B bromodomain</gtr:description><gtr:id>58D7AFD4-E469-43BE-9490-B32028B52E0F</gtr:id><gtr:impact>13. Ferguson, F.M., Dias, D.M., Rodrigues, J.P.G.L.M., Wienk, H., Boelens, R., Bonvin, A.M.J.J., Abell, C., Ciulli, A.* Binding hotspots of BAZ2B bromodomain: histone interaction revealed by solution NMR driven docking. Biochemistry, 2014, 53(42), 6706-6716.</gtr:impact><gtr:outcomeId>5464d1fa0bf0b5.68057454-1</gtr:outcomeId><gtr:partnerContribution>Provided access to NMR facility and provided intellectual input and expertise</gtr:partnerContribution><gtr:piContribution>Purified proteins to be used in NMR spectroscopic studies and binding assyas, and provided intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Cellzome Ltd</gtr:department><gtr:description>Chemoproteomics of native protein complexes</gtr:description><gtr:id>6C0C7DD9-585F-4E52-8AC1-974AEC5AAA38</gtr:id><gtr:impact>Bulatov, E., Martin, E.M., Chatterjee, S., Knebel, A., Shimamura, S., Konijnenberg, A., Johnson, C., Zinn, N., Grandi, P., Sobott, F., Ciulli, A.* Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2):ElonginBC:Cullin5:RING-box protein 2 (Rbx2). J. Biol. Chem. 2015, 290(7), 4178-4198.

Galdeano, Julianty et al. under revision</gtr:impact><gtr:outcomeId>5464c21002e077.56309962-1</gtr:outcomeId><gtr:partnerContribution>They performed chemoprotemics studies with our compounds, involving pull-down assays from cell lysates and mass spectrometric measurements to assess composition of recruited proteins and binding affinities of compounds</gtr:partnerContribution><gtr:piContribution>We provided Cellzome with compounds to be used in chemoproteomics studies to recruit native E3 Ubiquitin ligase protein complexes</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Media press release: Bump-and-hole approach brings protein breakthrough</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F3F2176B-E190-4AFE-A455-B4F8CDF28A9E</gtr:id><gtr:impact>Media press release covering my laboratory recent article published in Science

After this press release, I have received a notable number of emails from other colleagues and friends to congratulate us with our achievement but also to tell me that they read the press release and this stimulated their interest in learning more about the topic of epigenetics and small molecule chemical biology and drug discovery. Many individuals have already contacted me to make requests for reagents, and many companies interested in this area have also approached me to express their willingness and interest to collaborate with us.

see:
http://www.bbsrc.ac.uk/news/health/2014/141020-pr-bump-and-hole-brings-protein-breakthrough.aspx
http://www.lifesci.dundee.ac.uk/news/2014/oct/22/ciulli-labs-bump-and-hole-approach-leads-protein-breakthrough</gtr:impact><gtr:outcomeId>5464cd37c993d6.86468700</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbsrc.ac.uk/news/health/2014/141020-pr-bump-and-hole-brings-protein-breakthrough.aspx</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Participation at the CLS Open Doors Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9F712FBF-0A2E-4D2A-9060-A69D55F09169</gtr:id><gtr:impact>Our Institute Postdocs, PhD students, Support Staff, Facility Heads and PIs organized the Dundee College of Life Sceinces CLS Open Doors Day with great success on Saturday 8 November. Julianty Juliant, PhD student in my laboratory, participated.


We had over 400 people between 10am and 4pm and most of them stayed for over 2 hours. There's been amazing feedback and notes of thanks from members of the public, as well as requests from parent and kids asking us to visit their schools.
The most glowing praise was for our scientist/participants:- one lady summarises the main gist of the feedback by saying she found &amp;quot;the scientists just wonderful in their enthusiasm and explanations of the research they are conducting.&amp;quot;</gtr:impact><gtr:outcomeId>5464ce6b71a993.68081284</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.lifesci.dundee.ac.uk/news/2014/nov/10/well-done-and-thank-you-everyone-who-participated-open-doors-day-2014-saturday</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Carles Galdeano (Ciulli Lab) to attend the 65th Lindau Nobel Laureate Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A12B0D2C-0A17-4CD1-9FB8-A06D59BAD3DC</gtr:id><gtr:impact>Carles Galdeano of the Ciulli Group participated in the 65th Lindau Nobel Laureate Meeting, that was held from 28 June to 3 July 2015, in Lindau, Germany. The annual Lindau Nobel Laureate Meetings provide a globally recognised forum for the transfer of knowledge between generations of scientists. This interdisciplinary meeting, brings together Nobel Laureates and the next generation of talented scientists from the field of physiology and medicine, physics and chemistry to inspire and motivate Nobel Laureates and international &amp;quot;best talents&amp;quot;. 

Lectures of Nobel Laureates reflect current scientific topics and present relevant fields of research of the FUTURE. In panel discussions, seminars and during the various events of the social programme, young researchers nominated by a worldwide network of academic partners interact with Nobel Laureates. The meetings of Nobel Laureates in chemistry, physiology or medicine and in physics have been held since 1951. 70 Nobel Laureates and 672 selected early-career researchers from 88 countries will participate in the 2015 meeting.</gtr:impact><gtr:outcomeId>56ddcbdaa2bbe8.99664441</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www.lifesci.dundee.ac.uk/news/2015/apr/15/carles-galdeano-ciulli-lab-attend-65th-lindau-nobel-laureate-meeting</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alessio delivers the course Drug Discovery to the Dept. of Pharmaceutical Chemistry at the University of Messina, under the realm of the new MIUR-funded programme Messaggeri della Conoscenza</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>52F4790E-13A2-4FFF-B67A-B0C8085C4FAB</gtr:id><gtr:impact>Taught a course in Drug Discovery which sparked questions, discussions and further interaction. Hosted 4 selected students in my laboratory the following year, and disseminated all activities, also in the form of a video publicly accessible online

Students, teachers and public in Italy more aware of the important of exchange programmes between Italy and UK</gtr:impact><gtr:outcomeId>5464cf74901bc3.49889026</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=GxrQwJO9HB8</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>99000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC/Dundee College of Life Sciences (CLS) PhD Studentship</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>University of Dundee</gtr:fundingOrg><gtr:id>4C9E2F90-67A3-45A7-B0B6-6BAE8BC93BDA</gtr:id><gtr:outcomeId>54623758d15340.29282800</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>64000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>College of Life Sciences</gtr:department><gtr:description>Dundee College of Life Sciences (CLS) PhD Studentship</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>University of Dundee</gtr:fundingOrg><gtr:id>277B9B50-1A11-47A3-A8DA-B82BE09B6365</gtr:id><gtr:outcomeId>56d964a0678d37.67656336</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>Sweden, Kingdom of</gtr:country><gtr:currCode>SEK</gtr:currCode><gtr:currCountryCode>Sweden</gtr:currCountryCode><gtr:currLang>sv_SE</gtr:currLang><gtr:description>Foundation BLANCEFLOR Boncompagni-Ludovisi Fellowship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Foundation Blanceflor Boncompagni Ludovisi, n????e Bildt</gtr:fundingOrg><gtr:id>AF9AB20E-E95A-4B12-B4A5-25EF423903BA</gtr:id><gtr:outcomeId>56d968da83f3e1.67321725</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>0</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC ALERT14 High throughput bio-layer interferometry at Dundee</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/M012425/1</gtr:fundingRef><gtr:id>EF1CB1AB-791E-49BB-A246-3C958D6EAB83</gtr:id><gtr:outcomeId>58cb1447352251.59385042</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC EASTBIO Doctoral Training Partnership PhD Studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/J01446X/1</gtr:fundingRef><gtr:id>9482313F-1487-4BD4-A947-C9FAAB0F5F6B</gtr:id><gtr:outcomeId>546247a10cf2d4.56740622</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>24000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC/Dundee College of Life Sciences (CLS) PhD Studentship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>49284A18-5CCA-4C55-BDBC-CD18AE49AA00</gtr:id><gtr:outcomeId>546237de521094.28542764</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>107977</gtr:amountPounds><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Foundation of Science and Technology (FCT)</gtr:department><gtr:description>Portuguese FCT Studentship</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>Government of the Portugese Republic</gtr:fundingOrg><gtr:fundingRef>SFRH/BD/92417/2013</gtr:fundingRef><gtr:id>A4582565-75EB-4EB1-B746-1869F9EF9BC5</gtr:id><gtr:outcomeId>54623861be13c4.36168525</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>Italy, Italian Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>MIUR Messaggeri della Conoscenza - Drug Discovery</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Italian Ministry of Education, Universities and Research</gtr:fundingOrg><gtr:fundingRef>ID 497 - Drug Discovery</gtr:fundingRef><gtr:id>B297B7BF-1E2B-47F5-8DFE-9AA84C6EA04D</gtr:id><gtr:outcomeId>546236c8f069a8.05766206</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Marie Curie Intra-European Fellowships for Career Development (IEF)</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>EU FP7-PEOPLE-2012-IEF 328030 orthoPROTACS</gtr:fundingRef><gtr:id>26376255-E7BB-4343-AD18-F0A246B75717</gtr:id><gtr:outcomeId>546235cecb94e1.66043653</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>183000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EC Horizon 2020 - Marie Sklodowska Curie Individual Fellowship</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>705705 Anchor E3s</gtr:fundingRef><gtr:id>3D45612B-78FE-4622-9F6F-4F94629896E6</gtr:id><gtr:outcomeId>56d966596bfba3.07067814</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>0</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research collaboration with Boehringer Ingelheim</gtr:description><gtr:fundingOrg>Boehringer Ingelheim</gtr:fundingOrg><gtr:id>7BE4050B-CFA1-4A51-B74C-7F0FDF115BB2</gtr:id><gtr:outcomeId>58cb13b8ca52b8.14388950</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ERC Starting Grant: DrugE3CRL</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:fundingRef>ERC Starting Grant 311460 DrugE3CRLs</gtr:fundingRef><gtr:id>E9CD512F-1D57-4448-9B0E-E203A3588641</gtr:id><gtr:outcomeId>5462355b7f7df2.07191448</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>151392</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust 4 years PhD studentship</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>102398/Z/13/Z</gtr:fundingRef><gtr:id>39B56B6A-7791-409C-B15F-20A253462D7D</gtr:id><gtr:outcomeId>54648ad3159c29.27134367</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>183000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EC Horizon 2020 - Marie Sklodowska Curie Individual Fellowship</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>655516 Bump-BET</gtr:fundingRef><gtr:id>C2F0ECC8-A8A2-4C18-B726-05B25A60F02B</gtr:id><gtr:outcomeId>56d965c70dce43.41563316</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>132000</gtr:amountPounds><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Foundation of Science and Technology (FCT)</gtr:department><gtr:description>Portuguese FCT Studentship</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Government of the Portugese Republic</gtr:fundingOrg><gtr:fundingRef>SFRH/BD/101598/2014</gtr:fundingRef><gtr:id>7E7AEDE2-D355-464A-9D31-CE3575462452</gtr:id><gtr:outcomeId>56d9636c3a27a3.84416756</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>63000</gtr:amountPounds><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Coordination of Higher Education Personnel Training (CAPES)</gtr:department><gtr:description>CAPES/Dundee PhD Studentship</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Government of Brazil</gtr:fundingOrg><gtr:fundingRef>7148-14-3</gtr:fundingRef><gtr:id>C3B43E34-434C-458A-8763-1D63E6BB3C91</gtr:id><gtr:outcomeId>56d965331ec7c9.60873467</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The breakthrough discoveries made by our laboratory and collaborators of potent VHL ligands have led not only to several publications, but also two patents (US 2014356322 and WO 2013106646), and to the establishment of Yale spin-off Arvinas in the US and a Discovery Platform Unit (DPU) within GlaxoSmithKline Stevenage, UK. Such activity represents tangible output of Dr. Ciulli's research in terms of impact, innovation and commercial exploitation. Arvinas and the GSK DPU are pharmaceutical companies both focused on developing small molecule strategies aimed at degrading disease- causing cellular proteins, with a focus in oncology amongst other therapeutic areas.

One breakthrough was the design of super-targeted inhibitors, which have exquisite selectivity for honing in on individual BET bromodomains (protein interaction modules that bind acetyl-lysine), without affecting the many other such domains in a cell. The trick was a novel `bump-and-hole' approach that matches the inhibitors to dual features of the target sites (Science, 2014, 346, 638-641). 

In a further twist, the Ciulli Lab developed a new class of compounds that do not just block BET proteins, but spark a process of degradation, which eventually destroys with exquisite selectivity the cognate protein (ACS Chem Biol, 2015, 10, 1770-1777). This is achieved by means of hetero-bifunctional molecules known as PROteolysis TArgeting Chimeric molecules (PROTACs) that targets the selected protein to the ubiquitin-proteosome degradation pathway using an E3 ligase ligand that the group had previously discovered (J Med Chem, 2014, 57, 8657-8663). Since proteins containing BET bromodomains play crucial roles in many cellular physiological pathways relevant to health and disease, the compounds have exciting potential to accelerate development of therapeutic drugs with minimal side effects and toxicity. Following these discoveries, Dr Ciulli and the University are engaged in confidential discussions to partner with pharmaceutical companies.

Dr Ciulli and the UoD have filed two patents relating to the new approaches (patent number WO/2015/079259
 http://www.freepatentsonline.com/WO2015079259A3.html; and Patent Application No. GB 1504314.4, Filing Date: March 13, 2015).</gtr:description><gtr:firstYearOfImpact>2012</gtr:firstYearOfImpact><gtr:id>73EEF476-A00E-4A8F-A4C7-61614A7F7C21</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56df0934b3ec36.04755405</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The University of Dundee and the authors have filed a patent application (GB1504314.4) related to the use of BET bromodomain targeting PROTACs to induce degradation of BET proteins.

Patent Application No. GB 1521858.9 &amp;amp; GB 1504314.4 (Priority Date: March 13, 2015)
PCT HGF Ref. P227094WO / FE (filing date March 14, 2016)
WO 2016/146985 (International publication date September 22, 2016)</gtr:description><gtr:grantRef>BB/G023123/2</gtr:grantRef><gtr:id>99621186-30F6-4D8D-BC54-9710A629AC79</gtr:id><gtr:impact>Impact yet to be realised.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>56ddd00babaf46.80419332</gtr:outcomeId><gtr:patentId>WO 2016/146985</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl)carbonylaminomethyl]-4-(1,3-thiazol-5-yl) benzene which are useful for the treatment of proliferative, autoimmune or inflammatory diseases</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>1) VHL-HIF inhibitors. In collaboration with Craig Crews (Yale University), we have discovered first-in-class small molecules that bind the E3 CRL component von-Hippel Lindau protein (VHL) and disrupt its interaction with substrate Hypoxia Inducible Factor alpha subunit (HIFa) (Van Molle et al., Chem. Biol., 2012; Buckley et al., J. Am. Chem. Soc. 2012; Angew. Chem. Int. Ed. 2012). More recently, my laboratory conducted extensive rational design, guided by liganded crystal structures and biophysical binding characterization, to improve the binding affinity and physicochemical properties of the compounds (Galdeano et al., J. Med. Chem 2014). These exciting discoveries and the resulting filed patents have led to the establishment of spin-off company Arvinas in the U.S. and of a Discovery Platform Unit (DPU) in Protein Degradation within GSK.

2) PROTACs. We have designed molecules based on the discovered VHL ligands, to induce intracellular removal of proteins of interest via the ubiquitin-proteasome system by hijacking and directing proteins to VHL. Such chimaeric molecules (PROTACs) act as chemical degraders of the target as opposed to just inhibitors and more closely phenocopy traditional gene knockdown tools e.g. RNAi. We have recently shown that a compound linking the pan-selective bromo and extraterminal (BET) bromodomain inhibitor JQ1 to our VHL ligand not only induces potent dose- and time-dependent destruction of BET proteins, but crucially is selective for Brd4 over other BET members Brd2 and Brd3, leading to a more limited Brd4-specific transcriptional response when compared to that of pan-inhibitor JQ1 (Zengerle et al., ACS Chem. Biol. 2015). This now provides unprecedented opportunities to study the physiological and therapeutic consequences of intra-BET selective modulation of the drug target Brd4.

3) Ligandability of CRLs. Using the VHL-HIFa inhibitors as a starting point, we have carried out fundamental analyses of what type of ligands can more effectively probe PPIs and what approaches can best find these molecules (Van Molle et al., Chem. Biol., 2012; Dias et al., ACS Med. Chem Lett., 2014). This research is increasing our understanding of the druggability of PPIs, which helps to intervene effectively and reduce risks associated with tackling such challenging targets.

4) CRL complexes. Using a hybrid approach combining biophysical and structural techniques in innovative ways, and in collaboration with experts in ion-mobility native mass spectrometry (Dr. Djana Matak-Vinkovic, Cambridge and Prof Frank Sobott, Antwerp) and chemoproteomics (Dr Paola Grandi, GSK-Cellzome), we have dissected in increasing level of detail the molecular structure, assembly and interactions of components of complexes and their PTMs within the CRL5-ASB9 (Thomas et al., Biochemistry, 2013) and CRL5-SOCS2 (Bulatov et al., J. Biol. Chem., 2015; Gadd et al., Plos One, 2015).</gtr:description><gtr:exploitationPathways>by exploiting their potential as chemical tools and therapeutics</gtr:exploitationPathways><gtr:id>3E65D5BA-C32C-4230-ABF6-46BC51D633FE</gtr:id><gtr:outcomeId>56df0a3b8bfca1.75894708</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.lifesci.dundee.ac.uk/groups/alessio-ciulli</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>compounds related to patent Enzyme Function Probes
Patent Application No. 1320994.5 &amp;amp; 1401001.1 (Priority Date: 28 Nov 2013)</gtr:description><gtr:id>FF5DD383-F5D4-4817-91A0-80BBC527B513</gtr:id><gtr:impact>paper just published in Science
impact to see full realization in due course</gtr:impact><gtr:outcomeId>5464d3f3ecc867.36330395</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>chemical genetics bump-and-hole approach to engineer controlled selectivity of BET bromodomain inhibitors</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.lifesci.dundee.ac.uk/groups/alessio-ciulli/news/just-published-science-our-paper-describing-chemical-genetics-bump-and-hole-approach-engineer</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl)carbonylaminomethyl]-4-(1,3-thiazol-5-yl) benzene which are useful for the treatment of proliferative, autoimmune or inflammatory diseases
Patent Application No. GB 1521858.9 &amp;amp; GB 1504314.4 (Priority Date: March 13, 2015)
PCT HGF Ref. P227094WO / FE (filing date March 14, 2016)
WO 2016/146985 (International publication date September 22, 2016)</gtr:description><gtr:id>75ED0376-5B1A-47E6-8E4C-1C81A2158AF1</gtr:id><gtr:impact>Paper published in 2014 ACS Chem Biol</gtr:impact><gtr:outcomeId>56ddcc911ed941.37675987</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>chemical biology PROTAC approach to small-molecule induced target protein degradation</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.chemicalprobes.org/mz1</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Chemical strategies to using small molecules to stimulate hypoxia inducible factors (HIFs) activity and trigger a hypoxic response under normoxic conditions, such as iron chelators and inhibitors of prolyl hydroxylase domain (PHD) enzymes, have broad-spectrum activities and off-target effects. Here we disclose VH298, a potent VHL inhibitor that stabilizes HIF-a and elicits a hypoxic response via a different mechanism, that is the blockade of the VHL:HIF-a protein-protein interaction downstream of HIF-a hydroxylation by PHD enzymes. We show that VH298 engages with high affinity and specificity with VHL as its only major cellular target, leading to selective on-target accumulation of hydroxylated HIF-a in a concentration- and time-dependent fashion in different cell lines, with subsequent upregulation of HIF-target genes at both mRNA and protein levels. VH298 represents a high-quality chemical probe of the HIF signalling cascade and an attractive starting point to the development of potential new therapeutics targeting hypoxia signalling.</gtr:description><gtr:id>84211E81-E275-43AB-BF0F-0137D318250C</gtr:id><gtr:impact>? Highlighted in Drug Discovery Today
? Highlighted in ScienceDaily;</gtr:impact><gtr:outcomeId>58cb1648e1b456.16652652</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>VHL inhibitor VH298: a new chemical probe of hypoxia signaling</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.chemicalprobes.org/vh298</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E0A729E1-4C0F-46BA-B629-BD3300BF847C</gtr:id><gtr:title>Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2595b4a7cfd27964cd44b6e1b564763"><gtr:id>e2595b4a7cfd27964cd44b6e1b564763</gtr:id><gtr:otherNames>Galdeano C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>54648b49af02a5.91817814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07A205E4-216D-4F78-88C2-54B6AAE59422</gtr:id><gtr:title>Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2595b4a7cfd27964cd44b6e1b564763"><gtr:id>e2595b4a7cfd27964cd44b6e1b564763</gtr:id><gtr:otherNames>Galdeano C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn><gtr:outcomeId>585d3e5be5edf1.37229493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F01813B0-789D-4947-8FC1-F66DD39344DC</gtr:id><gtr:title>Structural basis of molecular recognition of helical histone H3 tail by PHD finger domains.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5c3c2645482aba69d5ccd90273204e2"><gtr:id>a5c3c2645482aba69d5ccd90273204e2</gtr:id><gtr:otherNames>Bortoluzzi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>5a6ad438d83e32.09812095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93EEA538-E093-4458-B090-5678A6B9FA94</gtr:id><gtr:title>Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd022f2a0dd7d6b6f0330e226d06c264"><gtr:id>bd022f2a0dd7d6b6f0330e226d06c264</gtr:id><gtr:otherNames>Baud MGJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>54648b4951f337.39631105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91EAE0B4-2D03-407A-8C5D-D38D7B44109A</gtr:id><gtr:title>Mind the Metal: A Fragment Library-Derived Zinc Impurity Binds the E2 Ubiquitin-Conjugating Enzyme Ube2T and Induces Structural Rearrangements.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0f852f4cb03c66bc8c03cff94a63194"><gtr:id>b0f852f4cb03c66bc8c03cff94a63194</gtr:id><gtr:otherNames>Morreale FE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>5a2fce38b2ffb4.23890638</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B93B759-2CB5-430B-BE90-D7B8D170D09F</gtr:id><gtr:title>Gram-Scale Laboratory Synthesis of TC AC 28, a High-Affinity BET Bromodomain Ligand</gtr:title><gtr:parentPublicationTitle>ACS Omega</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14bc1ac6eea0328f343aef5b9f6dd0f0"><gtr:id>14bc1ac6eea0328f343aef5b9f6dd0f0</gtr:id><gtr:otherNames>Khan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a2fd169a395d9.87408123</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF09696E-BA79-436F-A2D3-09C46607E36F</gtr:id><gtr:title>Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein-Protein Interactions?</gtr:title><gtr:parentPublicationTitle>ACS medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b41655ec6cfb913faa9ce0aaa91d7cf0"><gtr:id>b41655ec6cfb913faa9ce0aaa91d7cf0</gtr:id><gtr:otherNames>Dias DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1948-5875</gtr:issn><gtr:outcomeId>54648c454d9da9.18242294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BC66BDA-69A8-4A3B-A9B6-E2281D79D1DE</gtr:id><gtr:title>Cyclic and Macrocyclic Peptides as Chemical Tools To Recognise Protein Surfaces and Probe Protein-Protein Interactions.</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7343ce13c197911d9eda22d246542411"><gtr:id>7343ce13c197911d9eda22d246542411</gtr:id><gtr:otherNames>Cardote TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1860-7179</gtr:issn><gtr:outcomeId>56d6d31276d740.74628896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFE88636-9077-4A54-BE23-C60501DEFD37</gtr:id><gtr:title>Interactions, assembly and fragment screening of the multisubunit SOCS2-EloBC-Cul5-Rbx2 E3 ubiquitin ligase</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41b3de4d227e96cec8fd1f843260e613"><gtr:id>41b3de4d227e96cec8fd1f843260e613</gtr:id><gtr:otherNames>Bulatov Emil</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5464cb23798435.25668803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A9B47D5-A065-407E-AF2E-72F8ABAA4EC7</gtr:id><gtr:title>Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298).</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc84ae61af4c035816454b007b4f1d6b"><gtr:id>bc84ae61af4c035816454b007b4f1d6b</gtr:id><gtr:otherNames>Soares P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>5a2fcd4050aa99.95432017</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2976AB3C-DE1E-4AE3-AD74-6B9D67FAFF69</gtr:id><gtr:title>Allosteric Targeting of the Fanconi Anemia Ubiquitin-Conjugating Enzyme Ube2T by Fragment Screening.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0f852f4cb03c66bc8c03cff94a63194"><gtr:id>b0f852f4cb03c66bc8c03cff94a63194</gtr:id><gtr:otherNames>Morreale FE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>5a2fce5f96dac8.08429893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAF19159-4B88-4DFE-A4DA-2BF6DE91C51D</gtr:id><gtr:title>A novel approach to engineer selectivity of bromodomain chemical probes</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d531ef8a7c93341199bb6ed8f84285"><gtr:id>31d531ef8a7c93341199bb6ed8f84285</gtr:id><gtr:otherNames>Alessio Ciulli (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5464b16810a558.96163563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48EF7332-F1DD-478C-AEA6-47993C965675</gtr:id><gtr:title>Binding hotspots of BAZ2B bromodomain: Histone interaction revealed by solution NMR driven docking.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98971b7b99422190e6dd2ca3fdd2950e"><gtr:id>98971b7b99422190e6dd2ca3fdd2950e</gtr:id><gtr:otherNames>Ferguson FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>54648b498d7369.57733838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28511564-1784-44AD-8682-844E98250695</gtr:id><gtr:title>Potent and selective chemical probe of hypoxic signalling downstream of HIF-a hydroxylation via VHL inhibition.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c36182d31f035d5a4ce9190ed5086edc"><gtr:id>c36182d31f035d5a4ce9190ed5086edc</gtr:id><gtr:otherNames>Frost J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c9f76fb70095.51816162</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A3722FF-5818-476B-BB1F-1B3814CFA24D</gtr:id><gtr:title>Molecular basis of histone tail recognition by human TIP5 PHD finger and bromodomain of the chromatin remodeling complex NoRC.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5fc71630c08928905cfee490fcc0fb5"><gtr:id>a5fc71630c08928905cfee490fcc0fb5</gtr:id><gtr:otherNames>Tallant C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>5464b83519d407.16717096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D59C11D-779A-4161-85A5-E4438C24D7AD</gtr:id><gtr:title>New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6f5b6d9d45da6947e03cf0095933fb8"><gtr:id>e6f5b6d9d45da6947e03cf0095933fb8</gtr:id><gtr:otherNames>Baud MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>56d6d2b78ca825.35551028</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>565DBFF2-06D8-4767-BAF8-951A11350DEE</gtr:id><gtr:title>Multimeric complexes among ankyrin-repeat and SOCS-box protein 9 (ASB9), ElonginBC, and Cullin 5: insights into the structure and assembly of ECS-type Cullin-RING E3 ubiquitin ligases.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c4d6f6138fd6bd9d704db192be26001"><gtr:id>0c4d6f6138fd6bd9d704db192be26001</gtr:id><gtr:otherNames>Thomas JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>54648c459998a3.88077493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D0CFA43-FCC7-4065-B768-DFD15360BB0E</gtr:id><gtr:title>Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2)-elongin BC-cullin 5-ring box protein 2 (RBX2).</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95f82d1838b6e50a181a9bccf589c569"><gtr:id>95f82d1838b6e50a181a9bccf589c569</gtr:id><gtr:otherNames>Bulatov E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5675ddc64e47c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7667128C-9741-4B89-9327-3F110E5CCF17</gtr:id><gtr:title>Biophysical screening for the discovery of small-molecule ligands.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e36715ebcc37ef7255f27df8cf9cf78"><gtr:id>9e36715ebcc37ef7255f27df8cf9cf78</gtr:id><gtr:otherNames>Ciulli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>54648c4615e513.39374053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFEB1BAA-33CC-4B95-9535-A611C3A6E42F</gtr:id><gtr:title>Chemical genetics approaches for selective intervention in epigenetics.</gtr:title><gtr:parentPublicationTitle>Current opinion in chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f2d5e3d5a103a12bb3bae0f1eb83641"><gtr:id>3f2d5e3d5a103a12bb3bae0f1eb83641</gtr:id><gtr:otherNames>Runcie AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1367-5931</gtr:issn><gtr:outcomeId>585d348fc709a3.99427196</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47480850-03D0-44A6-BC02-485C93375BC8</gtr:id><gtr:title>Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/defc9be019ed40b5d5b42e5afa6ef2a7"><gtr:id>defc9be019ed40b5d5b42e5afa6ef2a7</gtr:id><gtr:otherNames>Zengerle M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>5675e5b3c2cdb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DA5DF7F-C2B8-426A-B2C2-667F6D3B1035</gtr:id><gtr:title>Optimization of a &amp;quot;bump-and-hole&amp;quot; approach to allele-selective BET bromodomain inhibition</gtr:title><gtr:parentPublicationTitle>Chemical Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ed3fbe48819113e9303e42aabbb1b42"><gtr:id>9ed3fbe48819113e9303e42aabbb1b42</gtr:id><gtr:otherNames>Runcie A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a981eecea72b7.30640514</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32916523-960B-47ED-939A-EFE18ECF3EBA</gtr:id><gtr:title>Serendipitous SAD Solution for DMSO-Soaked SOCS2-ElonginC-ElonginB Crystals Using Covalently Incorporated Dimethylarsenic: Insights into Substrate Receptor Conformational Flexibility in Cullin RING Ligases.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cad2b40a955b692fba0474cf6776934"><gtr:id>8cad2b40a955b692fba0474cf6776934</gtr:id><gtr:otherNames>Gadd MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675e784d2be7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99A56CEA-3FE0-4FF5-B098-B40A952941AC</gtr:id><gtr:title>Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95f82d1838b6e50a181a9bccf589c569"><gtr:id>95f82d1838b6e50a181a9bccf589c569</gtr:id><gtr:otherNames>Bulatov E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>doi_55f94b94bdc8a0f4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DB0975B-61A3-421D-9584-5B6DE8179D53</gtr:id><gtr:title>Target validation: Switching domains.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e36715ebcc37ef7255f27df8cf9cf78"><gtr:id>9e36715ebcc37ef7255f27df8cf9cf78</gtr:id><gtr:otherNames>Ciulli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn><gtr:outcomeId>58c9f70c5288c8.87885520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9060A6E-FEF6-4EE8-83C1-B0D2F1872502</gtr:id><gtr:title>A novel approach to engineer selectivity of bromodomain chemical probes</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d531ef8a7c93341199bb6ed8f84285"><gtr:id>31d531ef8a7c93341199bb6ed8f84285</gtr:id><gtr:otherNames>Alessio Ciulli (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5464b24fd445e8.24992320</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>314F2F0A-0A4D-436D-B728-8561C309A56A</gtr:id><gtr:title>NMR approaches in structure-based lead discovery: recent developments and new frontiers for targeting multi-protein complexes.</gtr:title><gtr:parentPublicationTitle>Progress in biophysics and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b41655ec6cfb913faa9ce0aaa91d7cf0"><gtr:id>b41655ec6cfb913faa9ce0aaa91d7cf0</gtr:id><gtr:otherNames>Dias DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0079-6107</gtr:issn><gtr:outcomeId>54648c45246049.65563279</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/G023123/2</gtr:identifier></gtr:identifiers><gtr:projectHierarchy><gtr:parents><gtr:parent><gtr:id>356968E7-9B59-4466-8470-563879CCAF7C</gtr:id><gtr:grantRef>BB/G023123/1</gtr:grantRef><gtr:amount>907791.74</gtr:amount><gtr:start>2010-01-01</gtr:start><gtr:end>2013-04-07</gtr:end><gtr:children><gtr:child rel="Transfer"><gtr:id>0E81F16A-93CA-4CE4-9ED6-1FB701974D46</gtr:id><gtr:grantRef>BB/G023123/2</gtr:grantRef><gtr:amount>307126.04</gtr:amount><gtr:start>2013-04-08</gtr:start><gtr:end>2015-07-07</gtr:end><gtr:children/></gtr:child></gtr:children></gtr:parent></gtr:parents></gtr:projectHierarchy><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>